News and Views


Nature Medicine 14, 495 - 496 (2008)
doi:10.1038/nm0508-495

Bench to bedside: BRCA: From therapeutic target to therapeutic shield

Neil P Shah1

  1. Neil P. Shah is in the Department of Hematology/Oncology, University of California, San Francisco, 505 Parnassus Avenue, Suite M1286, Box 1270, San Francisco, California 94143, USA.
    e-mail: nshah@medicine.ucsf.edu


Three studies examine how resistance to chemotherapy develops in cancers deficient in BRCA1 and BRCA2. The mechanism involves restoration of BRCA1 and BRCA2 activity. Shah examines the implications for the clinic, such as the potential value of continuing treatment with cisplatin and similar agents even after drug resistance develops.

Top


MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.

NEWS AND VIEWS

Cisplatin and the sensitive cell

Nature Medicine News and Views (01 May 2003)

Cancer Crossing over to drug resistance

Nature News and Views (28 Feb 2008)


Extra navigation

Subscribe to Nature Medicine

Subscribe

Search PubMed for

Open Innovation Challenges

naturejobs

ADVERTISEMENT